EMJ Oncology [Supplement 3] . 2022

In this issue

In this interview, they discuss the role of direct oral anticoagulants (DOAC) as a treatment for cancer-associated thrombosis (CAT), including updates to the guidelines and the importance of patient-centric care. A discussion of key unmet needs as described by the two experts and a look to the future of anticoagulation in patients with cancer is also included.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given